David A. Siegel Takeda Pharmaceutical CO LTD Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$15.28 - $16.48 $870,822 - $939,211	56,991 Added 184.38%	87,900 $1.45 Million
Q4 2022 Feb 14, 2023	SELL	$12.42 - $15.62 $1.07 Million - $1.35 Million	-86,491 Reduced 73.67%	30,909 $482,000
Q3 2022 Nov 14, 2022	SELL	$12.8 - $28.65 $794,329 - $1.78 Million	-62,057 Reduced 34.58%	117,400 $1.52 Million
Q2 2022 Aug 15, 2022	BUY	$13.12 - $15.03 $492,747 - $564,481	37,557 Added 26.47%	179,457 $2.52 Million
Q1 2022 May 16, 2022	BUY	$13.54 - $15.35 $1.92 Million - $2.18 Million	141,900 New	141,900 $2.03 Million
Q2 2021 Aug 16, 2021	SELL	$16.55 - $18.64 $1.67 Million - $1.88 Million	-100,800 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.71 - $19.9 $1.68 Million - $2.01 Million	100,800 New	100,800 $1.84 Million

320

70.4M

939K

233K

Ticker TAK
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 3,109,050,112
Market Cap $43.1B
Description
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived t...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.